Acorda Therapeutics Current Ratio 2006-2021 | ACOR

Acorda Therapeutics current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Acorda Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.11B $0.07B 1.67
2021-03-31 $0.19B $0.13B 1.43
2020-12-31 $0.22B $0.14B 1.61
2020-09-30 $0.15B $0.14B 1.09
2020-06-30 $0.16B $0.14B 1.14
2020-03-31 $0.17B $0.07B 2.38
2019-12-31 $0.20B $0.09B 2.33
2019-09-30 $0.31B $0.09B 3.42
2019-06-30 $0.36B $0.09B 3.81
2019-03-31 $0.42B $0.10B 4.30
2018-12-31 $0.53B $0.14B 3.77
2018-09-30 $0.55B $0.14B 4.03
2018-06-30 $0.50B $0.12B 4.09
2018-03-31 $0.43B $0.12B 3.65
2017-12-31 $0.44B $0.14B 3.07
2017-09-30 $0.30B $0.11B 2.77
2017-06-30 $0.26B $0.11B 2.39
2017-03-31 $0.25B $0.12B 2.08
2016-12-31 $0.27B $0.15B 1.84
2016-09-30 $0.24B $0.12B 2.01
2016-06-30 $0.26B $0.14B 1.93
2016-03-31 $0.54B $0.11B 5.18
2015-12-31 $0.45B $0.09B 4.98
2015-09-30 $0.43B $0.09B 4.61
2015-06-30 $0.43B $0.11B 3.83
2015-03-31 $0.42B $0.12B 3.47
2014-12-31 $0.39B $0.11B 3.42
2014-09-30 $0.84B $0.10B 8.36
2014-06-30 $0.69B $0.10B 7.33
2014-03-31 $0.36B $0.10B 3.84
2013-12-31 $0.37B $0.10B 3.80
2013-09-30 $0.39B $0.09B 4.39
2013-06-30 $0.41B $0.10B 4.26
2013-03-31 $0.39B $0.10B 4.04
2012-12-31 $0.33B $0.10B 3.37
2012-09-30 $0.29B $0.08B 3.57
2012-06-30 $0.33B $0.09B 3.70
2012-03-31 $0.35B $0.08B 4.24
2011-12-31 $0.36B $0.09B 4.13
2011-09-30 $0.33B $0.07B 4.49
2011-06-30 $0.31B $0.08B 3.70
2011-03-31 $0.31B $0.09B 3.47
2010-12-31 $0.31B $0.09B 3.31
2010-09-30 $0.30B $0.09B 3.35
2010-06-30 $0.26B $0.07B 3.73
2010-03-31 $0.29B $0.09B 3.21
2009-12-31 $0.29B $0.07B 4.02
2009-09-30 $0.31B $0.07B 4.80
2009-06-30 $0.34B $0.07B 4.61
2009-03-31 $0.24B $0.05B 4.78
2008-12-31 $0.26B $0.06B 4.80
2008-09-30 $0.28B $0.05B 5.75
2008-06-30 $0.16B $0.05B 3.54
2008-03-31 $0.18B $0.05B 3.88
2007-12-31 $0.11B $0.04B 2.83
2007-09-30 $0.12B $0.04B 3.28
2007-06-30 $0.12B $0.04B 3.06
2007-03-31 $0.06B $0.03B 1.95
2006-12-31 $0.07B $0.04B 1.86
2006-09-30 $0.03B $0.03B 1.20
2006-06-30 $0.04B $0.02B 1.52
2006-03-31 $0.04B $0.03B 1.56
2005-12-31 $0.03B $0.04B 0.71
2005-09-30 $0.00B 0.00
2005-06-30 $0.00B 0.00
2005-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.046B $0.153B
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86